youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
SRPT:NASDAQ
Sarepta Therapeutics Inc
$18.32
arrow_downward
-1.61%(-0.30) 1D
$18.30
arrow_downward
-0.11% (-0.020)bedtimeAfter hours
Closed: Nov 2, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SRPT...
Open
$18.65
High
$18.90
Low
$18.10
Mkt. cap
1.94B
Avg. vol.
2.64M
Volume
0.00
52-wk high
$24.68
52-wk low
$14.68
EPS
-$1.66
Beta
0.38
Shares outstanding
105.63M
No. of employees
835
Open
$18.65
High
$18.90
Low
$18.10
Mkt. cap
1.94B
Avg. vol.
2.64M
Volume
0.00
52-wk high
$24.68
52-wk low
$14.68
EPS
-$1.66
Beta
0.38
Shares outstanding
105.63M
No. of employees
835
News stories
From web sources and news partners
marketscreener.com
·
26 minutes ago
S&P 500 index fell sharply after Stockholm exchange close Monday
BigGo Finance
·
13 minutes ago
Nasdaq Vice Chairman Warns: Taiwan Stocks Climb to World's Fourth Largest, but 79% AI Exposure Tops the Globe
Quantisnow
·
49 minutes ago
Pershing Square USA, Ltd. Releases Third Quarter 2026 Portfolio Review
MarketWatch
·
8 hours ago
Nasdaq Inc. stock outperforms competitors on strong trading day
Profile
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. Wikipedia
About Sarepta Therapeutics Inc
Analyst ratings
Based on 17 analysts giving stock ratings to SRPT in the past 3 months
Hold
Buy
3
Hold
10
Sell
4
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for SRPT in the last 3 months.
Highest
Current $18.32
$38.00 (+107.42%)
Average
$21.53 (+17.52%)
Lowest
$5.00 (-72.71%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Tazeen Ahmad Bank of America Securities | Sell | Maintained | $18.00 | -1.7% | 11/02/2026 |
Mitchell Kapoor H.C. Wainwright | Sell | Maintained | $5.00 | -72.7% | 10/30/2026 |
Brian Abrahams RBC Capital | Hold | Maintained | $17.00 | -7.2% | 10/27/2026 |
Yun Zhong Wedbush | Buy | Maintained | $35.00 | +91% | 10/26/2026 |
Ritu Baral TD Cowen | Hold | Maintained | $17.00 | -7.2% | 10/21/2026 |
Biren Amin Piper Sandler | Hold | Maintained | $20.00 | +9.2% | 10/19/2026 |
Unknown Analyst Leerink Partners | Hold | Reiterated | $20.00 | +9.2% | 10/15/2026 |
Yanan Zhu Wells Fargo | Buy | Maintained | $38.00 | +107.4% | 10/02/2026 |
Anupam Rama J.P. Morgan | Hold | Reiterated | $20.00 | +9.2% | 09/30/2026 |
Lachlan Hanbury Brown William Blair | Hold | Reiterated | - | - | 09/28/2026 |
Gil Blum Needham | Sell | Maintained | - | - | 09/28/2026 |
Yigal Nochomovitz Citi | Sell | Maintained | $13.00 | -29% | 09/27/2026 |
Gavin Clark-Gartner Evercore ISI | Hold | Maintained | $19.00 | +3.7% | 08/10/2026 |
Eliana Merle Barclays | Hold | Maintained | $20.00 | +9.2% | 08/07/2026 |
Kristen Kluska Cantor Fitzgerald | Hold | Maintained | $21.00 | +14.6% | 08/05/2026 |
Kostas Biliouris Oppenheimer | Buy | Maintained | $35.00 | +91% | 08/06/2026 |
Michael Ulz Morgan Stanley | Hold | Reiterated | $25.00 | +36.5% | 08/06/2026 |
Uy Ear Mizuho Securities | Buy | Maintained | $31.00 | +69.2% | 07/10/2026 |
Andy Chen Wolfe Research | Buy | Upgraded | $27.00 | +47.4% | 07/08/2026 |
Stephen Brozak WBB Securities | Buy | Maintained | $38.00 | +107.4% | 03/26/2026 |
Unknown Analyst WBB Securities | Buy | Maintained | $38.00 | +107.4% | 03/26/2026 |
David Hoang Deutsche Bank | Sell | Maintained | $14.00 | -23.6% | 03/26/2026 |
William Pickering Bernstein | Hold | Maintained | $20.00 | +9.2% | 03/25/2026 |
Joseph Schwartz Leerink Partners | Hold | Maintained | $15.00 | -18.1% | 03/25/2026 |
Unknown Analyst Guggenheim | Buy | Reiterated | $19.00 | +3.7% | 03/09/2026 |
Brian Skorney Robert W. Baird | Hold | Maintained | $20.00 | +9.2% | 02/26/2026 |
Salveen Richter Goldman Sachs | Hold | Maintained | $17.00 | -7.2% | 02/25/2026 |
Sami Corwin William Blair | Hold | Reiterated | - | - | 02/26/2026 |
Next call in 3 days
Thu, Nov 5, 4:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.36
Revenue / Est. (USD)
- / 350.10M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 399.36M | 442.93M | 730.80M | 401.25M |
Cost of goods sold | 369.66M | 724.04M | 262.73M | 240.64M |
Cost of revenue | 369.66M | 724.04M | 262.73M | 240.64M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 91.89M | 128.30M | 108.95M | 107.60M |
Operating expense | 92.57M | 128.97M | 109.64M | 108.32M |
Total operating expenses | 462.24M | 853.02M | 372.37M | 348.96M |
Operating income | -62.88M | -410.08M | 358.43M | 52.29M |
Other non operating income | -702.00K | -338.00K | 1.16M | -246.00K |
EBT including unusual items | -194.05M | -278.30M | 343.17M | -1.75M |
EBT excluding unusual items | -63.90M | -423.20M | 344.24M | 36.74M |
Income tax expense | -14.10M | 4.55M | 12.22M | 3.14M |
Effective tax rate | 7.27% | -1.64% | 3.56% | -179.59% |
Other operating expenses | - | - | - | - |
Net income | -179.95M | -282.85M | 330.96M | -4.89M |
Net profit margin | -45.06% | -63.86% | 45.29% | -1.22% |
Earnings per share | -0.13 | -3.58 | 3.16 | 0.64 |
Interest and investment income | 7.25M | 8.07M | 6.36M | 6.21M |
Interest expense | -7.56M | -20.84M | -21.71M | -21.51M |
Net interest expenses | -316.00K | -12.77M | -15.35M | -15.30M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -44.43M | -404.83M | 369.03M | 62.70M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events